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Abstract 
Objectives 
Systemic sclerosis-associated pulmonary arterial hypertension differs from idiopathic 
pulmonary arterial hypertension regarding histopathology, treatment responses and 
survival. Progress is hampered by the lack of human biosamples and suitable animal 
models. Herein, we evaluated Fra-2 transgenic mice as a novel model for systemic 
sclerosis-associated pulmonary arterial hypertension. 
  
Methods 
Lung sections of Fra-2 transgenic (n=12) and wildtype mice (n=6) were analyzed at 
16 weeks by histology using Dana Point criteria. Cellular and molecular key players 
were assessed by immunohistochemistry. To test the model’s sensitivity to change 
over treatment, a subgroup of Fra-2 transgenic mice (n=6) was treated with the 
tyrosine kinase inhibitor nilotinib at 2x 37.5mg/d p. o. from 8 weeks of age. 
 
Results 
Fra-2 transgenic mice developed severe vascular remodeling of pulmonary arteries 
and nonspecific interstitial pneumonia-like interstitial lung disease resembling human 
systemic sclerosis-associated pulmonary hypertension. Histological features typical 
for systemic sclerosis-associated pulmonary arterial hypertension such as intimal 
thickening with concentric laminar lesions, medial hypertrophy, perivascular 
inflammatory infiltrates, adventitial fibrosis, but not pulmonary occlusive venopathy 
were frequently detected. Platelet-derived growth factor signaling pathways were 
activated in pulmonary vessels of Fra-2 transgenic compared to wildtype mice. Since 
treatment with nilotinib strongly prevented the development of proliferative 
vasculopathy and lung fibrosis, the model proved to be sensitive to treatment. 
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Conclusions 
Our study suggests Fra-2 transgenic mice as an animal model of systemic sclerosis-
associated pulmonary arterial hypertension that displays main characteristic features 
of the human disease. It therefore allows studying pathophysiological aspects and 
might serve as a preclinical model for interventional proof of concept studies. 
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To date, pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) 
account for more than 60% of the SSc-related mortality (1). 
Patients with SSc-PAH have a worse prognosis and response to PAH-specific 
therapies than patients with idiopathic PAH (IPAH) or PAH related to other 
connective tissue diseases (2-4). The observed differences in SSc-PAH and the 
frequent co-existence of ILD (5) support the concept of a specific pathophysiology of 
SSc-related pulmonary hypertension (PH), and two recent studies suggested 
remarkable histopathological differences of the vascular lesions associated with IPAH 
and those related to SSc-PAH (6, 7). 
Since research is hampered by the lack of human biosamples, animal models 
are of outmost importance to 1) study pathophysiological interactions between the 
different lung manifestations, to 2) identify molecular key players and potential 
therapeutic targets and 3) for preclinical proof of concept studies. Unfortunately, there 
is a shortage of validated animal models of SSc that simultaneously display features 
of ILD and pulmonary vasculopathy (8), whereas established animal models of PAH 
rather reflect features of human IPAH than SSc-PAH (9).  
The Fra-2 (Fos-related antigen-2) transgenic (tg) mouse model combines 
vasculopathy with fibrosis of the skin and internal organs, and Fra-2 protein is 
overexpressed in the skin and lungs of patients with SSc (10, 11). The aim of our 
study was to analyze Fra-2 tg mice as a potential animal model of SSc-PH (1) by 
exploring whether it displays the histopathological features considered specific for 
SSc-PAH, (2) by characterizing key cellular and molecular pathways contributing to 
the SSc-PAH specific features and (3) by assessing its sensitivity to change over 
treatment. 
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Materials and Methods 
Additional information on methods is provided in the online Data Supplement. 
 
Animals 
A subgroup of Fra-2 tg mice (10, 11) (n=6) was treated with nilotinib 2x37.5 
mg/d and compared to vehicle-treated Fra-2 tg mice and wildtype (wt) littermates 
(n=6 each). Fra-2 tg mice were backcrossed from a mixed (C57BL/6×CBA) genetic 
background on a pure C57/Bl6 background for at least six generations (11). 
 
Histology 
Lung sections were prepared as described previously (12). Sections were 
stained with hematoxylin and eosin (HE) and Masson’s trichrome staining according 
to standard protocols. 
 
Immunohistochemistry 
For primary and secondary antibodies refer to data supplement. 
 
Analysis of histological and immunohistochemical stainings 
All slides were analyzed by two blinded independent examiners. Pictures were 
taken with a digital camera on an Imager1 microscope (Carl-Zeiss AG, Feldbach, 
Switzerland), using AxioVision software Release 4.6. 
Pulmonary histopathology was assessed by microscopic criteria including 
pattern and distribution of inflammation, deposition of extracellular matrix, and 
architectural changes (13). Vascular histopathology was analyzed according to the 
Dana point consensus criteria (14).  
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Vascular remodeling was assessed by calculating the median(Q1,Q3) of vessel wall 
thickness and the percentage of luminal occlusion of pulmonary arteries using 
GraphPad Prism software.  
Cellular key players were identified by double staining with PCNA as 
proliferation marker and the respective cell markers for vascular smooth muscle cells 
(α-SMA+SM22α+) and myofibroblasts (α-SMA+). Manually counted positive nuclei 
within vessel walls were confirmed independently by automated counting using 
image analysis software (Image J, NIH). 
To assess differences in the expression of platelet-derived growth factor-BB 
and p(phosphorylated)-PDGFRβ, positively stained vascular cells were analyzed by 
automated analysis of staining intensity (0=no, 1=weak, 2=moderate, and 
3=intensive staining) using Image J. The median(Q1,Q3) of staining intensity was 
calculated using Graph Pad Prism software. 
For the analysis of inflammatory infiltrates, stains for T-cells (CD3+) and 
murine macrophages (F4/80+) as well as double stainings with PDGF-BB/p-PDGFRβ 
were performed. 
 
Statistical analysis  
Nonparametric nonrelated data were analyzed with the Mann-Whitney-U test 
and expressed as median(Q1,Q3). P-values<0.05 were considered statistically 
significant. Power calculation was performed using STATA 10.0 (StataCorp, College 
Station, Texas). 
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Results 
Pulmonary pathology of Fra-2 tg mice resembles changes in SSc-PH 
Pulmonary vasculopathy 
To investigate Fra-2 tg mice as a potential model for SSc-PAH, we analyzed 
features of pulmonary vascular remodeling. 
Increase in wall thickness and occlusion of pulmonary arteries were the most 
prominent features of pulmonary pathology in Fra-2 tg (Fig.1B) compared to wt mice 
(Fig.1A). Semiquantitative analysis of vascular remodeling showed that in Fra-2 tg 
mice the thickness of vessel walls was strongly increased compared to wt mice 
(median(Q1,Q3) 44(32,59)μm vs. 21.5(13,36)μm; p<0.0001) (Fig.1C). Obliterated vessels 
were almost undetectable in wt mice (0(0,1)%), whereas the percentage of obliterated 
vessels was increased to 33(33,53)% in Fra-2 tg mice (p=0.04) (Fig.1D). 
We next evaluated the histopathology of pulmonary vessels according to the 
DANA point criteria (14) (table 1). 
 
Table 1: Pathologic characteristics of vasculopathies in pulmonary hypertension 
 Definition according to 
Dana point 
(adapted from (14) 
Presence 
in Fra-2 tg 
mice 
Changes 
characteristic 
for human 
SSc-PAH 
(6, 7) 
Changes 
characteristic 
for human 
IPAH 
(6, 7) 
Concentric laminar 
intimal thickening 
expansion of (myo-
)fibroblasts, smooth muscle 
cells (SMCs) 
+++ 
(Fig.1E) 
+++ (+) 
Concentric and 
eccentric 
nonlaminar 
thickening 
predominantly composed of 
fibroblasts/connective tissue 
+ 
(Figs.1F-G)  
+ + 
Adventitial 
thickening 
 ++ 
(Fig.1F) 
++ ++ 
Medial hypertrophy increase due to hypertrophy/-
plasia of SMCs, to an 
increase in connective tissue 
and elastic fibers, extension 
of SMCs into non-
muscularized arteries 
+ 
(Fig.1H) 
+ + 
Plexiform lesion focal proliferation of 
endothelial channels lined by 
myofibroblasts, SMCs, and 
connective tissue matrix 
- (+) +++ 
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Dilation lesion thin-walled vein-like vessel 
distally to a plexiform lesion 
- - + 
Arteritis rarely primary, often 
associated with 
plexiform/dilation lesions, 
arterial wall may be necrotic 
and/or be infiltrated with 
chronic and acute 
inflammatory cells  
- - + 
Perivascular 
inflammatory 
infiltrates 
 ++ 
(Fig.1H) 
++ + 
Interstitial changes fibrosis, inflammatory 
infiltrates 
+++ 
(suppl. 
Figs.1B-D) 
+++ (+) 
Pulmonary 
occlusive 
venopathy (POV, 
formerly PVOD) 
extensive and diffuse 
occlusion of pulmonary 
venules and veins, occluding 
fibrous tissue may be loose 
and edematous with variable 
cellularity or dense, sclerotic, 
and accellular; intimal 
thickening mainly involves 
venules and small veins, 
luminal occlusion can be 
solid or eccentric with 
multiple lumina; media may 
become thickened with an 
increase in elastic fibers and 
SMCs 
- ++ (+) 
Pulmonary 
microvasculopathy 
(PM, formerly 
PCH) 
localized capillary 
proliferation that invades 
pulmonary interstitium, 
vessels, and, less commonly, 
airways; panlobular and 
patchy distribution, 
often associated with 
pulmonary hemosiderosis 
- - - 
- absent, (+) hardly ever present/not characteristic, + rarely/can be observed, ++ often/common 
feature, +++ very often/characteristic feature  
 
In summary, Fra-2 tg mice developed several features that are considered more 
common in SSc-PAH than in IPAH. In contrast to human SSc-PH, pulmonary 
occlusive venopathy (POV, formerly PVOD) was not detectable in Fra-2 tg mice. 
 
Interstitial lung disease 
Given the frequent co-existence of ILD, we additionally examined the histology 
of interstitial lung changes (for details refer to data supplement). 
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In summary, Fra-2 tg mice developed a severe interstitial pneumonitis and fibrosis 
with concomitant lung emphysema (suppl. Fig.1) which closely resembled the 
features of human nonspecific interstitial pneumonia (NSIP), which is the main 
histological pattern in SSc-ILD (15). In contrast to a previous study (10), 
honeycombing, severe scarring or other pulmonary changes resembling human UIP 
were not observed which might be due to the different genetic background of the Fra-
2 tg mice. 
 
Cellular composition of intimal lesions 
We next characterized the cells driving the intimal thickening in Fra-2 tg mice. 
In wt mice, α-SMA (smooth muscle antigen) staining indicated muscular pulmonary 
vessels (Fig.2A). α-SMA+ myofibroblasts/vascular smooth muscle cells (VSMCs) 
(Fig.2B) were the most abundant cells within the neointima, whereas expansion of 
endothelial cells (van Willebrand factor (vWF)+) was not observed (Fig.2B). To 
differentiate between VSMCs and myofibroblasts, we performed additional stainings 
with antibodies against the VSMC-specific marker SM22α (smooth muscle 22α) 
(Figs.2C+D). In wt mice, VSMCs were mainly found within the walls of bronchi 
(Fig.2C), in Fra-2 tg mice, mainly in the media but not the intima of pulmonary 
vessels and in bronchiolar walls (Fig.2D). 
The proliferation marker PCNA (proliferating cell nuclear antigen) (Figs.2E+F) 
was abundantly expressed by myofibroblasts showing that the observed changes 
were due to proliferation and not hypertrophy of cells. 
In summary, mainly myofibroblasts and to a lesser extent VSMCs were key 
players in the remodeling of pulmonary arteries in Fra-2 tg mice which differs from 
the previous finding of VSMCs as the most abundant cells. This difference might 
either be due to technical reasons (no additional staining with a VSMC-specific 
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marker such as SM22α+) or due to the different genetic background of the Fra-2 tg 
mice. 
 
Molecular mechanisms of vascular remodeling: PDGF signaling 
Next, we assessed potential molecular mechanisms of both vasculopathy and 
ILD. In patients with IPAH, PDGF-BB has been proposed as a novel therapeutic 
target (16, 17), and a recent study reported a higher immunoreactivity for p-PDGFRβ 
in SSc-PAH compared to IPAH (18). 
Thus, we analyzed the expression of PDGF-BB and the phosphorylated 
(=activated) PDGFRβ in the lungs of Fra-2 tg and wt mice by assessing the staining 
intensity. Both, the expression of PDGF-BB (Fig.3B) and of p-PDGFRβ (Fig.3E) was 
increased in vascular structures of Fra-2 tg compared to wt mice (Figs.3A+D). 
Occasionally, increased staining for p-PDGFRβ could be observed in the alveolar 
epithelium of Fra-2 tg mice (Fig.3E). Semiquantitative analysis confirmed the 
substantially increased expression of PDGF-BB in pulmonary vessels in Fra-2 tg 
compared to wt mice (median(Q1,Q3) of staining intensity 3(2.8,3.0) vs. 0(0,1); p<0.0001) 
(Fig.3C). A similarly strong upregulation was observed for p-PDGFRβ (3(2,3) vs. 
0(0.0,0.3); p<0.0001) (Fig.3F). In addition to vascular structures, tissue macrophages 
(F4/80+) in Fra-2 tg mice showed a strong upregulation of both PDGF-BB (Fig.3G) 
and p-PDGFRβ (Fig.3H). These findings suggest a potential role for PDGF-BB in the 
pulmonary pathophysiology of Fra-2 tg mice. 
 
Nilotinib prevents vascular remodeling and fibrosis in Fra-2 tg mice 
Next we evaluated whether targeting the PDGF-BB/PDGFR pathway using the 
tyrosine kinase inhibitor nilotinib could modify the vascular and fibrotic lesions in Fra-
2 tg mice. 
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Pulmonary vasculopathy 
Treatment with nilotinib strongly prevented the remodeling of pulmonary 
arteries (Fig.4B) compared to vehicle-treated Fra-2 tg mice (Fig.4A). The endothelial 
cell layer (vWF+) was not affected upon treatment with nilotinib (Fig.4B) compared to 
wt mice (Fig.4A). Semiquantitative analysis showed that compared to vehicle-treated 
Fra-2 tg mice, in nilotinib treated Fra-2 tg mice both the thickness of vessel walls 
(median(Q1,Q3) 44(32,59) vs. 22.5(18,28)μm, p<0.0001) (Fig.4C) and the percentage of 
obliterated vessels (33(13,53)% vs. 0(0,7)%, p=0.03) (Fig.4D) was significantly reduced 
reaching the levels of wt mice. 
Treatment with nilotinib resulted in a reduced proliferation of α-SMA+ cells 
compared to vehicle-treated Fra-2 tg mice as analyzed by PCNA-double-staining 
(Figs.4F+E). These findings were confirmed by semiquantitative analysis with 
reduction of proliferating (PCNA+) α-SMA+ cells in nilotinib treated compared to 
vehicle-treated Fra-2 tg mice (median(Q1,Q3) 22(19,43) vs. 87(57,90) PCNA+ vascular 
cells/HPF) (Fig.4G). 
As expected, the expression of p-PDGFRβ (Fig.5B), and also of PDGF-BB (Fig.5E) 
was reduced in vascular structures compared to vehicle-treated mice (Figs.5A+D) 
showing successful targeting of PPDGFR. Semiquantitative analysis demonstrated a 
reduced staining intensity for p-PDGFRβ (Fig.5C) and also for PDGF-BB (Fig.5F) in 
the pulmonary vessels of nilotinib treated compared to vehicle-treated Fra-2 tg mice 
(median(Q1,Q3) 2(2.0,2.3) vs. 3(2.8,3.0), p=0.03; 1(0.8,1.0) vs. 3(2,3), p=0.004). 
 
Interstitial lung disease 
Treatment with nilotinib also inhibited the development of lung fibrosis in Fra-2 
tg mice when assessing the accumulation of connective tissue by Masson’s trichrome 
staining (Figs.5G+H). 
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Interestingly, treatment with nilotinib diminished the numbers of macrophages 
(Fig.5J, F4/80+), whereas T cells (Fig.5J, CD3+) were not affected compared to 
vehicle-treated Fra-2 tg mice (Fig.5K). However, there was a considerable 
heterogeneity between mice in the effects of nilotinib on inflammatory cells, and the 
differences to vehicle-treated mice did therefore not reach statistical significance in 
the semiquantitative analysis. 
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Discussion 
To date, there is substantial evidence on several levels  that SSc-PAH, though 
sharing similarities, substantially differs from IPAH and thus might warrant different 
therapeutic approaches. However, the development of targeted therapies is 
hampered by the lack of human biosamples of SSc patients and by the lack of 
suitable animal models for preclinical studies. 
Our study suggests Fra-2 tg mice as a potential model for SSc-PAH. The 
comprehensive histological and immunohistochemical analysis showed that Fra-2 tg 
mice displayed many pathologic changes characteristic for the vascular remodeling in 
human SSc-PAH (6, 7, 18). The model can however not be used to further delineate 
mechanisms underlying POV, as POV-specific features were not identified in our 
study. Besides vasculopathy, interstitial inflammation and fibrosis closely resembling 
human NSIP as the most common form of SSc-ILD could be observed. Fibroblastic 
foci and honeycombing, associated with UIP, were rarely detectable in our study, but 
were identified more frequently in a recent study (10). This might be explained by the 
different background of Fra-2 tg mice, as the mice in this study were backcrossed 
from a mixed (C57BL/6×CBA) genetic background on a pure C57/Bl6 background. 
However, besides allowing the evaluation of pathophysiologic mechanisms 
and in particular the interplay of pro-fibrotic and vascular processes, Fra-2 tg mice 
might also serve as a preclinical model for interventional proof of concept studies.  
The tyrosine kinase inhibitor nilotinib by blocking PDGFR signaling prevented the 
development of both proliferative pulmonary vasculopathy and fibrosis in Fra-2 tg 
mice which argues for SSc-specific therapies of PH. Furthermore, our data support 
previous studies on PDGF as key mediator of vasculopathy in SSc-P(A)H (17-19). 
Inhibition of PDGF signaling, e. g. by tyrosine kinase inhibitors, might be an example 
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of a promising future therapy for P(A)H (20) with particular evidence in SSc-PAH, as 
it targets vascular as well as fibrotic changes (21, 22).  
The role of Fra-2 as a potential key player for the development of (pulmonary) 
vasculopathy and fibrosis in SSc should be addressed in further studies. Recent data 
demonstrated an increased expression of Fra-2 in lung biopsies from patients with 
UIP, NSIP and SSc-associated NSIP (10). Based on previous data on 
microvasculopathy and dermal fibrosis in SSc patients (11, 23), a recent study 
demonstrated substantial anti-fibrotic effects of AP-1 inhibition in different animal 
models of SSc (24). Thus, Fra-2/AP-1 itself might represent an interesting molecular 
target for future SSc-specific therapies, even more so, since several pro-inflammatory 
chemokines and cytokines implicated in the pathogenesis of SSc were expressed in 
high levels in the lungs of Fra-2 tg mice including CXCL5, CCL2, IL-2, IL-4, IL-6 (10). 
Inhibition of these downstream targets with currently available drugs might elucidate 
further treatment options. AP-1 is induced by growth factors, cytokines and 
oncoproteins which are involved in the proliferation, survival, differentiation and 
transformation of cells (25). Whether Fra-2 related pathogenic changes in vivo might 
be accelerated by other factors such as pro-inflammatory stimuli or hypoxia (26) in 
pulmonary disease will have to be addressed in future studies.  
Taken together, the model of Fra-2 tg mice is the first animal model that 
simultaneously displays major histopathological features of pulmonary SSc, e. g. 
pulmonary proliferative vasculopathy and interstitial fibrosis, which occur frequently 
together in patients with SSc and are associated with a high mortality. Fra-2 tg mice 
hold great promise to further delineate the pathophysiological links between vascular 
remodeling and fibrosis in pulmonary SSc and to identify potential specific molecular 
and cellular targets for intervention. This study also underlines a prominent role of 
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PDGF in the pathophysiology of pulmonary SSc and suggests Fra-2 tg mice as a 
preclinical model for interventional proof of concept studies in pulmonary SSc. 
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Figure legends 
Fig. 1 Pulmonary pathology of Fra-2 tg mice: vascular remodeling 
(A) Pulmonary histology of wt mice (HE staining, arrow indicates vascular structure, B 
indicates bronchus). (B) Remodeling of pulmonary vessels with luminal narrowing 
and obliteration in Fra-2 tg mice (arrows; HE staining, B indicates bronchi). Figures 
C+D show the semiquantitative analysis with evaluation of vessel wall thickness and 
luminal obliteration in Fra-2 tg compared to wt mice. (E-H) illustrate the main 
pathologic changes of pulmonary vessels in Fra-2 tg mice: concentric laminar lesion 
due to formation of neointima by myofibroblasts and VSMCs (E, α-SMA positive, 
blue, short arrows) whereas the endothelial cell layer (vWF positive, red, long arrows) 
remained unaffected; (F) medial hypertrophy (arrow, HE staining) and perivascular 
inflammatory infiltrates (white asterisk), (G) adventitial fibrosis (Masson’s trichrome 
stain, bold arrow) and concentric laminar lesion (long arrow), and (H) eccentric 
nonlaminar lesion (Masson’s trichrome stain, arrow) due to expansion of fibroblasts 
and deposition of extracellular matrix proteins. Pictures are representative examples 
of 6 wt and 6 Fra-2 tg mice. Data are expressed as median and interquartile range. * 
indicates p-values <0.05 
 
Fig. 2 Cellular key players of vascular remodeling in Fra-2 tg mice 
Compared to wt mice (A), severe vascular remodeling of pulmonary arteries could be 
observed in Fra-2 tg mice (B). In Fra-2 tg mice, increase in vessel wall thickness 
occurred due to expansion of α-SMA positive cells (dark blue, short arrows), whereas 
the endothelial cell layer was not increased (vWF-positive, red, long arrows). 
Increase in vessel wall thickness was mainly due to myofibroblasts (α-SMA positive, 
SM22α negative), whereas VSMCs (α-SMA (blue) and SM22α (purple) positive) were 
mainly expressed in bronchiolar (B) walls in wt mice (C, arrows), and additionally in 
 21 
the media of muscular vessels in Fra-2 tg mice (D, arrows). (E) Formation of 
neointima was mainly due to proliferation of α-SMA-positive cells (dark blue, short 
arrows) as indicated by the double staining with the proliferation marker PCNA 
(brown, long arrows). (F) shows the proliferating cells in a higher magnification. 
Pictures are representative examples of 6 wt and 6 Fra-2 tg mice. 
 
Fig. 3 Molecular mechanisms of vascular remodeling in Fra-2 tg mice: PDGF 
signaling 
Compared to wt mice (A), in Fra-2 tg mice (B), vascular structures (short arrows) 
showed an increased staining for PDGF-BB (brown, long arrows) as shown in the 
semiquantitative analysis (C). The same difference could be observed for p-PDGFRβ 
(brown, long arrows; arrowhead indicates increased staining in the alveolar 
epithelium) in pulmonary vessels (bold arrow) of Fra-2 tg (E) compared to wt mice (D; 
bold arrow indicates vascular structure, arrows indicate staining in the interstitium). 
(F) shows the respective semiquantitative analysis. In addition, there was also an 
increased expression of PDGF-BB (G, brown) and its activated receptor (H, brown) in 
pulmonary macrophages (green, F4/80-positive, arrows). Pictures are representative 
examples of 6 wt and 6 Fra-2 tg mice. Data are expressed as median and 
interquartile range. * indicates p-values <0.05 
 
Fig. 4 Effects of nilotinib on vascular remodeling in Fra-2 tg mice 
Compared to vehicle-treated mice (A, short arrows), treatment with nilotinib strongly 
prevented the vascular remodeling of pulmonary arteries (B, short arrows). The 
endothelial cell layer was not affected (red, vWF positive cells, long arrows. (C+D) 
demonstrate the differences in vessel wall thickness and luminal obliteration in the 
semiquantitative analysis. As indicated by the double staining with the proliferation 
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marker PCNA (brown, long arrows) compared to vehicle-treated mice (E), the 
expansion of α-SMA-positive cells (blue, myofibroblasts and VSMCs, short arrows) 
was reduced upon treatment with nilotinib (F), additionally demonstrated in the 
semiquantitative analysis (G). Pictures are representative examples of 6 wt, 6 
vehicle-treated and 6 nilotinib treated Fra-2 tg mice. Data are expressed as median 
and interquartile range. * indicates p-values <0.05 
 
Fig. 5 Effects of nilotinib on PDGF signaling and interstitial lung disease 
Compared to vehicle-treated Fra-2 tg mice (A, D), the expression of both p-PDGFRβ 
(B, brown, long arrows) in vascular structures (short arrows) and PDGF-BB (E, 
brown, long arrows) was reduced by treatment with nilotinib. (C+F) show the results 
of the respective semiquantitative analyses. Interstitial fibrosis (appears green in 
Masson’s trichrome staining) (H) was strongly prevented by nilotinib compared to 
vehicle-treated Fra-2 tg mice (G). In 3 out of 6 mice, nilotinib (J) diminished the 
number of macrophages (F4/80 positive, green, arrows) compared to vehicle-treated 
mice (I) whereas CD3 positive cells (purple) remained unaffected. Pictures are 
representative examples of 6 wt, 6 vehicle-treated and 6 nilotinib treated Fra-2 tg 
mice. Data are expressed as median and interquartile range. * indicates p-values 
<0.05 
 
 
 
 
 
 
 
